ライフサイエンスコーパス: progression

1 cells-all collectively contributing to PDAC progression.

2 that are critical for cancer initiation and progression.

3 secondary prevention of respiratory allergy progression.

4 which were presumably undergoing more rapid progression.

5 small fibre neuropathy and to assess disease progression.

6 assess risk factors associated with HIV/AIDS progression.

7 ell lines, suggesting a role of KPNA4 in PCa progression.

8 aki fragment length by restricting Pol delta progression.

9 impact the susceptibility of children to OM progression.

10 d conditional miRNA regulation during cancer progression.

11 ges, a process that is essential for disease progression.

12 nts died, including seven because of disease progression.

13 ging to study this parameter during diabetes progression.

14 by nintedanib plus placebo monotherapy until progression.

15 lved in both circadian timing and life cycle progression.

16 ts driving cancer development and neoplastic progression.

17 irus (HIV) are at high risk of liver disease progression.

18 ion, cellular growth control, and cell-cycle progression.

19 ng the effects of obesity on prostate cancer progression.

20 rcome remyelination failure and halt disease progression.

21 other therapeutic modalities fail to prevent progression.

22 boembolic events, heart failure (HF), and AF progression.

23 us associations to various cancers and tumor progression.

24 HPV-stimulated aerobic glycolysis and tumor progression.

25 tion by slowing or impeding replication fork progression.

26 monstrated to play important roles in cancer progression.

27 d cytotoxicity does not drive kidney disease progression.

28 ut become functionally impaired upon disease progression.

29 r PEITC and PcG proteins in control of tumor progression.

30 t HIF-2alpha is essential for CRC growth and progression.

31 Ts, is known to promote tumor initiation and progression.

32 the transmitted virus play a role in disease progression.

33 identification of prognostic factors for CCC progression.

34 to receive nivolumab at the time of disease progression.

35 blockade of genes associated with cell cycle progression.

36 pposed to representing natural primary tumor progression.

37 ed significantly in patients without erosion progression.

38 19.8 months median survival from the time of progression.

39 in inflammation, in Alzheimer's disease (AD) progression.

40 may contribute to the modulation of disease progression.

41 lmarks that correlated with clinical disease progression.

42 f individual cells in the context of disease progression.

43 hat likely contribute to HPV-mediated cancer progression.

44 C) and the key drivers of its initiation and progression.

45 ifferent effects on cell behavior with tumor progression.

46 ancer, SIN3B provides a barrier to malignant progression.

47 l motility/contractility help mediate tumour progression.

48 a well-established suppressor of metastatic progression.

49 sary for kinetochore assembly and cell-cycle progression.

50 ic inflammation plays a primary role in ACLF progression.

51 into patient-specific predictions of disease progression.

52 uency of new immune patterns of response and progression.

53 r is a critical barrier to pancreatic cancer progression.

54 omatin to regulate genes relevant to disease progression.

55 ransforming proteins in HPV that drive tumor progression.

56 a critical step for end-stage liver disease progression.

57 as a critical immunomodulator in lung cancer progression, acting to drive immune escape via a C3/C5-d

58 At later stages, during cancer growth and progression, additional epigenetic changes triggered by

59 dependently associated with one-year disease progression after adjustment for traditional risk factor

60 bserved a reduction in CAF-facilitated HNSCC progression after blocking CAF autophagy.

61 -9 and sTRA had statistically longer time-to-progression after surgery.

62 For non-vaccine serotypes, rates of progression among Bedouin and Jewish children aged <12m

63 eterminant of subtype differences in disease progression among HIV-1 subtypes; furthermore, we propos

64 own to have prognostic value for clinical HD progression and brain atrophy.

65 ases, where they are associated with disease progression and chemorefractoriness.

66 nvolved in oxidative stress responses, tumor progression and chemoresistance.

67 Reduced rate of DNA replication fork progression and chromosomal shattering were also observe

68 treotide, PRRT reduced the hazard of disease progression and death by 79%.

69 acute infection predicts subsequent disease progression and drives CD4 decline independently of the

70 ch the tumor microenvironment controls tumor progression and endocrine resistance.

71 al use for monitoring HD mouse model disease progression and evaluating preclinical disease-modifying

72 k as an important driver of breast carcinoma progression and metastasis, these results lay the ground

73 ns, cardiovascular disease (CVD), and cancer progression and metastasis.

74 -3 may have an important influence on cancer progression and metastasis.

75 ost biological processes, I propose that the progression and outcome of disease-causing host-parasite

76 s controlled by these isoforms affect cancer progression and outcomes.

77 ssion), with the final aim of blocking their progression and preventing bowel damage and disability.

78 This may be important in slowing disease progression and provides insight into the protective rol

79 olorectal tumor stroma associates with tumor progression and reduced survival time of patients with m

80 mia as a driver of tumor initiation, disease progression and relapse.

81 eal transplant rejection, and attenuates the progression and severity of autoimmune diseases and expe

82 n DKO prostate tumorigenesis, slowed disease progression and significantly extended survival.

83 n-cell-autonomously to facilitate cell-cycle progression and stem cell proliferation.

84 iRNA whose activity may define breast cancer progression and survival.

85 have been attributed to increased cell cycle progression and the development of genomic instability w

86 y considered as an approach to combat cancer progression and therapeutic resistance, but a limited nu

87 (EMP2) correlates with endometrial carcinoma progression and ultimately poor survival from disease.

88 acidosis is a hallmark of tumor development, progression, and aggressiveness, the pHLIP technology ma

89 neity is a major driver of cancer evolution, progression, and emergence of drug resistance.

90 rent patients' risk factors for HCA, disease progression, and pathology features of tumors.

91 of HIV-1-controllers at risk for immunologic progression, and provide avenues for personalized therap

92 ogeneity, change in phenotype during disease progression, and resistance.

93 lipid biosynthetic pathways in driving CRPC progression, and suggest that ADTs may be therapeuticall

94 panded from PD-1(+) CD8 TILs contained tumor progression, and their efficacy was enhanced by PDL-1 bl

95 underlying disease prevention, pathogenesis, progression, and therapeutic intervention.

96 thermore, we show that growth and cell cycle progression are arrested in cells infected with vaccinia

97 indle pole localization of WDR62 and mitotic progression are defective in patient-derived fibroblasts

98 ps between Twist1 and Foxa1 in breast cancer progression are unknown.

99 nants of type 1 and type 2 diabetes risk and progression, as well as complications.

100 and progression; loss of Arf promotes tumor progression but not initiation.

101 SLE progression (but not onset) does not require the partici

102 asured by sj/beta-TREC ratio, in HIV disease progression by analyzing a large number of patients in 3

103 that a 0.1 Gy radiation dose reduces cancer progression by deactivating the JAK1/STAT3 pathway.

104 culation models were designed to mimic tumor progression by escalating flow complexity and chaoticity

105 B) contributes to atherosclerosis and cancer progression by processing the extracellular matrix and p

106 retinal cells that are highly prognostic for progression, can be followed and quantified reliably usi

107 a time that correlates well with meiosis II progression, concomitant with phospholipid remodeling.

108 er delineate a phenotypic roadmap of disease progression culminating in serially transplantable leuke

109 Meiotic progression depends on tight physical and functional cou

110 remained relatively steady and allowed good progression detection even in advanced disease.

111 n advanced glaucoma, GCC remains a sensitive progression detector from early to advanced stages.

112 e, 38%; stable disease [SD] or local disease progression [DP], 13%) versus 33% of high-grade tumors (

113 e-to-event analyses showed that OCT detected progression earlier than VF in both PG and GS/PPG groups

114 gnificant association between TIL values and progression-free survival (adjusted HR 0.95, 95% CI 0.90

115 th a complete response rate of 12.5%, median progression-free survival (PFS) of 14 months, and 2-year

116 Eligible studies reported MRD status and progression-free survival (PFS) or overall survival (OS)

117 At median follow-up of 15.6 months, progression-free survival (PFS) was 17.4 months and over

118 dy demonstrated a significant improvement in progression-free survival (PFS) with ixazomib-lenalidomi

119 ffusion coefficient (ADC) histogram metrics, progression-free survival (PFS), and overall survival.

120 OS, progression-free survival (PFS), and safety were analyze

121 r estimate were 72% (95% CI, 56% to 84%) for progression-free survival and 79% (95% CI, 63% to 89%) f

122 Progression-free survival and overall survival were seco

123 rapy is associated with improved overall and progression-free survival compared with conventional rad

124 including a patient with metastatic RCC with progression-free survival of > 3.9 years.

125 l, 27 patients with liposarcoma had a median progression-free survival of 237 days.

126 The estimated 10-year progression-free survival rates were 9.5% and 9.2% for t

127 Median progression-free survival was 2.8 months (95% CI 2.8-3.6

128 Median ITT progression-free survival was 5.2 months (95% CI, 3.2 to

129 Median progression-free survival was 6.0 (95% CI, 5.0 to 7.3) m

130 K pathway-activated patients (n=372), median progression-free survival was 6.8 months (95% CI 4.9-7.1

131 Progression-free survival was prolonged significantly in

132 Median progression-free survival was significantly improved in

133 Median progression-free survival was significantly longer in th

134 all survival, disease-specific survival, and progression-free survival were the primary end points.

135 weighted values of median overall survival, progression-free survival, response rate, and toxic effe

136 Despite somewhat prolonged progression-free survival, treatment with lomustine plus

137 kinases CDK4 and CDK6 substantially improve progression-free survival.

138 tating treatment did not result in prolonged progression-free-survival, fewer toxic effects, or impro

139 abolite changes that are associated with the progression from CHB to HBV-associated cirrhosis and ult

140 probiotics to colonized patients to prevent progression from colonization to infection.

141 Long-term SSRI treatment may delay progression from MCI to Alzheimer's dementia.

142 Selective breakdown of brain networks during progression from normal aging to Alzheimer disease demen

143 tion of autophagic flux, was associated with progression from steatosis to NASH in liver biopsies.

144 rexpression in subjects experiencing disease progression, further strengthening the relationship of t

145 es longitudinal data to characterize disease progression, heterogeneity, and severity in patients wit

146 Patients could be treated beyond progression if deriving apparent clinical benefit and to

147 n the posterior substantia nigra is a valid, progression imaging marker of Parkinson's disease, which

148 itis Research Society International grading (progression in 1st-, 2nd-, 3rd-, 4th-, 6th-, or 8th-year

149 l) levels were related with rate of clinical progression in a sample of 393 nondemented memory clinic

150 icate that R-ketorolac treatment slows tumor progression in an aggressive model of breast cancer.

151 possible biomarkers of disease severity and progression in bronchiectasis.

152 opical atropine for the prevention of myopic progression in children.

153 itotic length and interferes with cell-cycle progression in human cells, and it causes cell-cycle def

154 ced imaging showed promise for evaluating RP progression in human patients, and gene augmentation usi

155 icarbazone (3-AP) effectively suppresses PEL progression in immunodeficient mice.

156 ebrafish resulted in accelerated liver tumor progression in males.

157 Cell cycle progression in mammals is strictly controlled by a numbe

158 es, with aberrant expression linked to tumor progression in many cancers.

159 tivation, and measures of subsequent disease progression in multiple sclerosis patients.

160 inga), recent reports suggest slower disease progression in nonhuman primates.

161 The criterion for flagging progression in our simulation was a significant slope of

162 sociation of overweight/obesity with disease progression in patients with autosomal dominant polycyst

163 Disease progression in patients with chronic lymphocytic leukemi

164 lay an important role in tumor initiation or progression in smokers, representing novel therapeutic t

165 identified candidate MRs driving the disease progression in the innate immunity pathways.

166 ignificantly accelerates tumor initiation or progression in the prostate-specific Pten deletion mouse

167 s from (1) 13 patients who developed disease progression in the remnant pancreas following resection

168 We identified 3 mechanisms underlying local progression in the remnant pancreas: (1) residual micros

169 The meta-analysis of progression in TRACK-HD and REGISTRY gave a genome-wide

170 cinoma (ICC), we modeled ICC desmoplasia and progression in vitro.

171 Vibrational progressions in the NIPE spectra of ECX(-) were assigned

172 le analysis, factors associated with disease progression included use of HDCT as third-line or later

173 Disease progression includes composite mortality, hospitalizatio

174 back difference elevation (BDE), pachymetric progression index maximum(PPI max), and multimetric D we

175 When disease progression is abrupt, however, other coexisting disease

176 ne central adiposity on future periodontitis progression is conditional on proinflammatory IL-1 genet

177 ead, we showed that mycobacterial cell-cycle progression is regulated by an unprecedented mechanism i

178 feration rather than for allowing cell-cycle progression itself and must be regulated dynamically dur

179 was fair regarding questions about glaucoma progression (kappa, 0.39; 95% CI, 0.32-0.48) and conside

180 ss of p53 promotes both tumor initiation and progression; loss of Arf promotes tumor progression but

181 A liver disease progression Markov model, which used a lifetime horizon

182 rably and accurate information regarding CKD progression may improve clinical decisions.

183 ifferences on secondary endpoints of disease progression measuring cognition and function and hippoca

184 es are consistent with slow rates of disease progression (median doubling time: 84 days, 95% uncertai

185 pressure and albuminuria, and prevented CKD progression more effectively than eplerenone.

186 Prior endocrine regimens during which progression occurred included aromatase inhibitor (n = 3

187 developed HGD or EAC, with an annual rate of progression of 0.95%.

188 ndrial complex function to efficient lineage progression of adult NSCs and identify mitochondrial fun

189 onal pathways that are able to slow down the progression of Alzheimer's disease.

190 sed as fluorescent markers for following the progression of amyloidogenic processes.

191 eotides targeting mouse Angptl3 retarded the progression of atherosclerosis and reduced levels of ath

192 ticenter, prospective Natural History of the Progression of Atrophy Secondary to Stargardt Disease (P

193 may offer novel insights into the onset and progression of cancer and may provide specific and selec

194 pmental processes as well as the genesis and progression of cancers.

195 ar matrix plays a decisive role in malignant progression of carcinomas.

196 and metabolic pathologies, as well as in the progression of certain infectious diseases.

197 s of exosomes may promote development and/or progression of chronic inflammatory lung diseases includ

198 y, and it predisposes to the development and progression of CKD.

199 protein kinase 2 (Skp2) in the formation and progression of CRPC.

200 sulted in lower rates of the development and progression of diabetic kidney disease than placebo.

201 that targeting RAGE impairs inflammation and progression of diabetic vascular complications, cardiova

202 performance at baseline, but ameliorates the progression of dystrophic pathology.

203 from 3,987 subjects without diabetes in the Progression of Early Subclinical Atherosclerosis (PESA)

204 ternal supplies, and is essential for normal progression of embryogenesis.

205 nd that the tissue tropism broadens with the progression of gestation.

206 a indicate that Gab2 mediates the pathologic progression of HCC by integrating multiple signaling pat

207 Visual progression of IPH volume was present in 14 (26%) of the

208 ogical reports that aerobic capacity impacts progression of liver disease and suggest that these effe

209 eatedly used on a large scale to monitor the progression of liver pathology in schistosomiasis japoni

210 ces in understanding of the pathogenesis and progression of lung disease in cystic fibrosis (CF).

211 ncing of il17a in fibrotic mice arrested the progression of lung fibrosis, attenuated cellular apopto

212 an extracellular matrix molecule that drives progression of many types of human cancer, but the basis

213 in distinguishing multiple primary MCCs from progression of MCC clinically resembling multiple primar

214 ers for diagnosing, tracking, and predicting progression of mental health disorders.

215 robe the importance of lipid peroxidation in progression of NASH beyond simple steatosis.

216 hese two domains are most susceptible to the progression of neurocognitive impairment caused by agein

217 alpha-syn) is suggested to contribute to the progression of neuropathology in Parkinson's disease (PD

218 ASK1) in hepatocytes is a key process in the progression of nonalcoholic steatohepatitis (NASH) and a

219 ent of older men with low testosterone slows progression of noncalcified coronary artery plaque volum

220 The near-term progression of ocean acidification (OA) is projected to

221 omatin remodeling and in the development and progression of pancreatic cancer; however, the details o

222 Loss of IKBKE inhibits the initiation and progression of pancreatic tumors in mice carrying pancre

223 issues, which correlates intimately with the progression of patients.

224 Dectin 1 ligation accelerated the progression of PDA in mice, whereas deletion of Clec7a-t

225 may be involved in the pathogenesis and the progression of prion diseases, representing a valid tool

226 that innate immunity may be involved in the progression of PTSD, yet also identified candidate MRs d

227 wever, it remains to be fully elucidated how progression of secondary growth is properly controlled.

228 s, onset of polyps in adolescence, and rapid progression of some polyps to advanced adenomas.

229 Progression of subclinical CVD was defined by 10-year ch

230 Furthermore, 6C5 slowed down the progression of tau aggregation even after uptake had beg

231 ng glial tau transmission contributes to the progression of tauopathies.

232 by providing insights into the mechanisms of progression of Tgfbr2-deficient invasive transition zone

233 eyes were included in the estimation of the progression of the area of DDAF.

234 matitis depending on the timing of onset and progression of the disease in childhood is lacking.

235 generates sequences underlying the temporal progression of the song.

236 cular mechanisms which provoke the onset and progression of the syndrome are largely unknown.

237 dies are needed to determine the life course progression of these changes.

238 py have increased recanalization and reduced progression of thrombosis, compared with patients who do

239 ycle and are required for the initiation and progression of various malignancies.

240 setting) and a taxane (any setting) and with progression on two or more HER2-directed regimens in the

241 36 months; adjusted hazard ratio for disease progression or death, 0.65; P<0.001).

242 omal atrophy was noted in 26 patients (52%), progression or new-onset cataract was noted in 22 patien

243 Hazard of disease progression or recurrence was significantly increased fo

244 ith 560 mg ibrutinib orally once daily until progression or unacceptable toxicity.

245 2.5 mg/day) for 28-day cycles, until disease progression or unacceptable toxicity.

246 hokeratology was effective in slowing myopia progression over a twelve-year follow-up period and demo

247 ut few have assessed risk factors or symptom progression over time.

248 Malignant progression phenotypes were also affected at the level o

249 ents in 3 cohorts with different HIV disease progression phenotypes.

250 is important for cell signaling, cell cycle progression, polarity, and motility.

251 - in turn may become a determinant of cancer progression potential and prognosis.

252 s accumulate in SLO over the course of lupus progression, preferentially localizing near T lymphocyte

253 the lack of validated biomarkers of disease progression presents a challenge when developing new the

254 patic inflammation, fibrosis stage, fibrosis progression rate, hepatic infiltration of immune cells,

255 We also determined MELD progression rates for LABMELD patients.

256 a-articular anti-VEGF antibodies suppress OA progression, reduce levels of phosphorylated VEGFR2 in a

257 e survival (with an event defined as disease progression, relapse, death, allergy to rituximab, or se

258 P-43 contributes to disease pathogenesis and progression remain unclear.

259 d in the immune system, their role in cancer progression remains controversial.

260 ges directly regulate cancer development and progression remains poorly understood.

261 biota signatures of NAFL onset and NAFL-NASH progression, respectively.

262 ole in disease initiation as well as disease progression such as germ line predisposition, inflammati

263 enic and tumour-suppressing roles for cancer progression, such as the insulin-like growth factors.

264 ration of miR-874 expression impeded S phase progression, suppressing aggressive growth phenotypes, s

265 had significantly lower risk for clinical AL progression than non-drinkers (RR = 0.52; 95% CI: 0.30 t

266 Although these processes alter tumour progression, their regulation is poorly understood.

267 hypoxic BM microenvironment promotes disease progression, therapy resistance and relapse.

268 ing for drug resistance can drive metastatic progression, this study characterized the plasticity and

269 entify TIAM1 as a critical antagonist of CRC progression through inhibiting TAZ and YAP, effectors of

270 nscriptional activity and contributes to PCa progression through Siah2.

271 y, both proteins were found to promote tumor progression through the establishment of premetastatic n

272 ct regulator of transcription and cell cycle progression through the regulation of specific mRNA targ

273 study visit (day 336) and determined risk of progression to active tuberculosis disease over the subs

274 pment of castration resistance is pivotal in progression to aggressive disease.

275 netic mechanisms play a role in differential progression to CCC, but little is known about the role o

276 tohepatitis (NASH), which is associated with progression to cirrhosis and is rapidly becoming the lea

277 myocarditis induction but were required for progression to DCMi.

278 ot useful risk factors to measure to predict progression to death after coronary heart disease is est

279 ct is indicative of a reduced risk of future progression to end-stage renal disease.

280 ificantly suppressed cardiac hypertrophy and progression to heart failure in both vitamin D deficient

281 enotypic variability, phenotypic shifts, and progression to more aggressive disorders.

282 zero, probability of transition from disease progression to recovery (median 16% per year, 95% uncert

283 inally, patients with reduced EZH2 levels at progression to standard therapy responded to the combina

284 During the treatment-free phase, no progression toward advanced phase CML occurred, and all

285 zed and dynamically updated forecasts of OAG progression under different target IOP levels.

286 anges over time were correlated with disease progression using multivariate regression.

287 Yearly rate of progression using the growth of atrophic lesions measure

288 t plays important roles in metabolism, tumor progression, viral replication, and skin barrier formati

289 Visual field progression was assessed by PROGRESSOR software version

290 Radiographic JSN progression was evaluated by using Osteoarthritis Resear

291 joint-specific hard tissue diagnoses of DJD, progression was observed in 122 (15%) joints, no change

292 VF progression was reached if either the event or trend ana

293 Diagnostic reversal and progression were confirmed for both soft and hard tissue

294 activity, and effectively accelerates tumour progression when activated in advanced lung adenocarcino

295 t, it largely contributes to cardiac disease progression when dysregulated.

296 reak immunological tolerance and halt cancer progression, whereas on the contrary allergen immunother

297 ocated within the same hemifield that showed progression with a change of -1 dB/year or more (P < 0.0

298 mutated melanoma patients experience disease progression with targeted BRAF inhibitors, we hypothesiz

299 veillance (the serial monitoring for disease progression with the intent to cure) appears to be safe

300 (-/-) mice attenuated aneurysm formation and progression within the ascending, thoracic, and abdomina